Returning guest, Dr. Jeff Stark, MD, Head of US Medical Immunology at UCB discusses new data presented at the American College of Rheumatology (ACR) Convergence 2021 virtual congress on bimekizumab, UCB’s investigational IL-17A and IL-17F inhibitor from the Phase 2b BE AGILE study and its open-label extension data in ankylosing spondylitis (AS), and CIMZIA ® (certolizumab pegol), a TNF inhibitor, pivotal Phase 3 study evaluating the long-term safety and efficacy of CIMZIA in non-radiographic axial spondyloarthritis (nr-axSpA).
Jeffrey Stark, MD, is the Head of Medical Immunology at UCB and is board-certified in both rheumatology and internal medicine. After completing training at Vanderbilt University and Emory University, he spent several years in full-time rheumatology practice in both private and academic clinical settings. In subsequent industry medical affairs roles, Dr. Stark has focused on medical education, advocacy, data generation, and highlighting the unmet needs of patients with immunologic diseases. In addition to his role at UCB, Dr. Stark serves as a board member of the American College of Rheumatology (ACR) Research Foundation and is a member of the Medical Advisory Board of the Georgia Chapter of the Lupus Foundation. Dr. Stark is also a past President of the Georgia Society of Rheumatology.